The ALS Therapy Development Institute (ALS TDI), a drug discovery lab specializing in finding treatments for ALS, has announced plans to move its headquarters from Cambridge to Watertown, MASS. in order to support the growth of its research.
The new location will consist of a modern lab facility that will be tailored to accommodate its ALS research programs. The new facility is eight miles from downtown Boston in Watertown and is located at 480 Arsenal Way. The facility is approximately 16,000 square feet. Features include a main shared lab area, an animal care facility housing zebrafish and rodents and a translational research wing housing the Augie’s Quest Translational Research as well as a drug screening automation suite.
ALS TDI has made a number of advancements in ALS research, including discovering/inventing multiple potential treatments for ALS. One of the firm’s treatments, AT-1501, has been advanced directly from ALS TDI’s lab into human clinical trials.
David Cohen is Southeast Editorial Director at Connect Commercial Real Estate. David is a media veteran with more than 10 years of experience in journalism, copywriting and communications across a variety of roles. He is responsible for covering commercial real estate news and trends in the Southeast, Florida, Washington D.C. and Boston at Connect CRE as well as specializing in the Student Housing sector.
Prior to joining Connect, David was the editor of Northeast Real Estate Business magazine and Student Housing Business magazine at France Media as well as spending time freelancing for ESPN and the Associated Press in the fast-paced field of live sports event production. He is also an owner and investor in multifamily real estate in Atlanta, GA.
David currently resides in Atlanta and graduated from the College of Communication & Information at the University of Tennessee Knoxville.